A NephJC Shorts discussion of the long term data on kidney failure in FSGS and MCD

This week, we will discuss the clinical significance of eGFRdiff, the difference in eGFRcys (cystatin C) and eGFRcr (creatinine).

In just over a decade of critical appraisal on NephJC, we have done several experiments. Some of them have worked out phenomenally well, such as the Freely Filtered podcast. Others were not ready for ...

The ISN-Advancing Clinical Trials (ISN-ACT) is an ISN initiative to encourage existing infrastructures within ISN to improve the global nephrology community’s participation in clinical trial research.

YouTube video by University of Washington Division of Nephrology

The European Commission has granted standard approval to sparsentan for the treatment of adults with primary IgA nephropathy (IgAN).

This cohort study evaluates the association between sodium-glucose cotransporter 2 inhibitors and hyperkalemia in individuals with diabetes, heart failure, or chronic kidney disease receiving renin-an...

Patients on hemodialysis using a central venous catheter (CVC) are often advised not to shower due to infection risk. This study assessed practices and attitudes of patients and health care providers ...

ABSTRACT. Kidney disease frequently coexists with cardiovascular (CV) diseases, and this dual presence significantly amplifies the risk of adverse clinical

This systematic review and meta-analysis identifies reports of systematic reviews that included retracted studies in their meta-analyses, and assesses the impact of these retracted studies on the resu...

A study examined the effects of adding dapagliflozin to treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD).

Oral iptacopan (Fabhalta) has become the first FDA-approved treatment for proteinuria in adults with C3 glomerulopathy (C3G).

This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD.  These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, ...